Role of the Immune Environment in Response to Therapy in Breast Cancer

ClinicalTrials.gov ID: NCT05396612

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05396612. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Study identification

NCT ID: NCT05396612
Recruitment status: Recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Enrollment: 300 participants

Conditions and interventions

Conditions

Interventions

Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver. Other

Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 3, 2022 (Actual)
Primary completion: Dec 31, 2032 (Estimated)
Completion: Dec 31, 2032 (Estimated)
Last update posted: Jul 8, 2025

2022 – 2032

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Abramson Cancer Center	Philadelphia	Pennsylvania	19104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05396612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 8, 2025 · Synced Nov 13, 2026